Anti-emetic:Cancer chemotherapy Postoperative nausea and vomiting (PONV)
DOSE IN NORMAL RENAL FUNCTION
Chemotherapy: IV bolus or infusion: 100 mg —30 minutes before chemotherapyOral: 200 mg 1 hour before —chemotherapy, then 200 mg daily to prevent delayed nausea and vomitingPONV: IV bolus or infusion: 12.5 mg —Oral: 50 mg before induction of —anaesthesia
20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in normal renal function
HD                     :Unknown dialysability. Dose as in normal renal function
HDF/high flux   :Unknown dialysability. Dose as in normal renal function
CAV/VVHD      :Unknown dialysability. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAnti-arrhythmics: increased risk of ventricular arrhythmias – avoid concomitant useBeta-blockers: increased risk of ventricular arrhythmias with sotalol – avoid concomitant use
ADMINISTRATION
Reconstition
–
Route
Oral, IV bolus,
IV infusion
Rate of Administration
Bolus: over 30 seconds Infusion: over 15 minutes
Comments
Can be added to 50 mL sodium chloride 0.9%, glucose 5% or compound sodium lactate
OTHER INFORMATION
Peak concentrations occur 1 hour after oral and 0.6 hour after IV dosesOral bioavailability of 75% Active metabolite is renally excreted (approximately 30%)In patients with severe renal impairment (creatinine clearance
<10           : mL/min), maximum plasma levels of metabolite are increased 17% or 34%, respectively, after intravenous or oral administration of dolasetron, and systemic exposure is increased approximately 2-fold dolasetron mesilate.